TITLE

News Briefs

PUB. DATE
November 2010
SOURCE
American Journal of Health-System Pharmacy;11/15/2010, Vol. 67 Issue 22, p1900
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry in the U.S. including the withdrawal of sibutramine by Abbott Laboratories Inc. from the U.S. market, the signing of the Secure and Responsible Drug Disposal Act of 2010 on October 12, 2010, and the requirements of the Combat Methamphetamine Enhancement Act of 2010.
ACCESSION #
55040955

 

Related Articles

  • Targeting drug shortages: Feds move to ease supplies while prosecuting resellers. Lee, Jaimy // Modern Healthcare;2/27/2012, Vol. 42 Issue 9, p12 

    The article presents the issue of rising drug shortages as of February 2012. It discusses guidelines released by the U.S. Food and Drug Administration (FDA) in February 2012 regarding any production disruptions in companies that are sole drug manufacturers to ease shortages. Also reported are...

  • Appetite Suppressants May Cause Strokes.  // Environmental Nutrition;Dec2000, Vol. 23 Issue 12, p1 

    Reports the side effect of appetite suppressant drugs in the United States. Regulation of Food and Drug Administration to ban phenylpropanolamine (PPA)-containing drugs; Effect of PPA on the risk factor of strokes among women; Names of the appetite suppressant drugs.

  • What the FDA's Warning on PPA Means to Your Patients.  // Review of Optometry;12/15/2000, Vol. 137 Issue 12, p10 

    Reports that the United States Food and Drug Administration has issued a warning on the potential side effects of phenylpropanolamine, used by people with glaucoma who are taking beta blockers or alpha agonists. Federal agency's issuance of a public health advisory linking the risk of...

  • An Ingredient Under Fire. Noonan, David // Newsweek;10/30/2000, Vol. 136 Issue 18, p59 

    Focuses on a United States Food and Drug Administration advisory panel which declared that an ingredient found in decongestants and diet drugs was unsafe. Details of the ingredient which is known as phenylpropanolamine; How the drug is linked to causing stroke in women; Role of the Consumer...

  • Consumer group claims FDA failure. J.G.D. // Medical Marketing & Media;Feb2006, Vol. 41 Issue 2, p17 

    The article focuses on the claim by "Consumer Reports" that an investigation shows the U.S. Food and Drug Administration missed rare but serious side effects of 12 relatively common prescription drug types. These drug types include Celebrex, Accutane, Serevent, Meridia and Elidel.

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;10/16/2010, Issue 1323, p3 

    The article presents regulatory updates for therapeutic goods. Calcium supplements are now under review by Health Canada after a meta-analysis identified a potential link between the use of these supplements and the risk of myocardial infarction in patients with, or at risk of, osteoporosis....

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;2/7/2009, Issue 1238, p2 

    This section offers pharmacovigilance and regulatory news briefs. Consumers are advised by the U.S. Food and Drug Administration (FDA) not to use the dietary supplement Venom Hyperdrive 3.0 because it contains sibutramine that presents a significant risk for people with a history of heart...

  • Drugstore Chains Pull PPA-Containing Products in Response to FDA Warning. Hess, Glenn // Chemical Market Reporter;11/13/2000, Vol. 258 Issue 20, p22 

    Reports that several drugstore chains recalled nonprescription decongestants and diet drugs containing phenylpropanolamine (PPA) in response to the warning issued by the United States Food and Drug Administration. Adverse effect of the drug chemical; Reaction from the Consumer Healthcare...

  • FDA Warns Against Taking Venom HYPERDRIVE 3.0.  // Alternative Medicine Alert;Mar2009, Vol. 12 Issue 3, p36 

    The article reports on the warning issued by the U.S. Food and Drug Administration (FDA) against the intake of the dietary supplement Venom HYPERDRIVE 3.0. The product is said to contain the controlled substance sibutramine which poses risks for abuse or addiction. Side effects of the substance...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics